Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for Telmisartan and Hydrochlorothiazide tablets, used to treat high blood pressure (hypertension). The approved products are a generic version of Boehringer Ingelheim Pharmaceuticals Inc’s Micardis HCT tablets. Quoting IQVIA sales data for the 12-month period ending January 2019, Glenmark said the Micardis HCT tablets market achieved annual sales of approximately $40.6 million. The company’s stock gained 0.88 per cent at ₹604.35 on the NSE.